The long-term safety of ibrutinib was proven in patients with newly diagnosed or relapsed or refractory (R/R) chronic ...

The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future ...

Saad Z. Usmani, MD, MBA, FACP, discusses how the CEPHEUS study, presented at ASH 2024, along with its expanded analysis of minimal residual disease (MRD) outcomes, provides valuable insights into the ...

Trial confirms elinzanetant's efficacy and safety in addressing vasomotor symptoms caused by adjuvant endocrine therapy in ...

The bird flu, also known as avian influenza and H5N1, was implicated in the first human death from the infectious disease on ...

Researchers developed and validated a nomogram to predict 1-, 2-, and 3-year overall survival (OS) in patients with ovarian ...

Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA ...

Mistrust in health care, concerns over safety, and ineffective communication surrounding vaccines were among the themes ...

Vitiligo, a skin condition causing depigmentation, may significantly increase the risk of serious cardiovascular events.

Outcomes and care related to stroke in London, United Kingdom, were notably different based on ethnicity, with major ...

If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.

In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial ...